This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.
April 15, 2025
At the American Academy of Neurology Annual Meeting, we are delighted to share promising results from the ME&MGopen™ study, which aims to better understand generalized myasthenia through digital biomarkers.
These initial results reinforce the potential of our ME&MG digital tool to improve patient engagement and real-world understanding of this rare disease.
At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.
June 29, 2026
We announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA.
April 16, 2026
Ad Scientiam and Merck KGaA announce a new collaboration to improve care for people living with autoimmune myasthenia.
November 13, 2025
Talk to our experts and discover how our solutions integrate into your practice or studies.